BiondVax to Present at H.C. Wainwright 7th Annual Israel Conference
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced that CEO Amir Reichman will present a company overview at the H.C. Wainwright 7th Annual Israel Virtual Conference on Nov. 15, 2021, at 10:30 am ET. The biopharmaceutical company specializes in developing innovative products for infectious disease prevention and treatment. BiondVax has conducted eight clinical trials, including a Phase 3 trial with 12,400 participants. Investors interested in attending can register at H.C. Wainwright's website.
- None.
- None.
JERUSALEM, Nov. 15, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), which focuses on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced today that Chief Executive Officer Amir Reichman will present a company overview at the H.C. Wainwright 7th Annual Israel Virtual Conference today at 10:30 am ET.
Investors that wish to attend should register with H.C. Wainwright at https://hcwevents.com/israel/.
About BiondVax
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses. Since its inception, the Company has executed eight clinical trials including a seven country, 12,400 participant Phase 3 trial of its vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms. www.biondvax.com.
Contact Details
Company: Joshua E. Phillipson | +972 8 930 2529 | j.phillipson@biondvax.com
Investor Relations: Kenny Green | +1 212 378 8040 | kgreen@edisongroup.com
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements regarding management's participation in investor conferences. These forward-looking statements reflect management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. Risks and uncertainties include, but are not limited to, the risk that BiondVax will not execute a definitive agreement with the Max Planck Society and the University Medical Center Göttingen; the risk that the therapeutic and commercial potential of VHH antibodies will not be met; the risk that proof-of-concept studies and clinical trials in VHH antibodies will not occur, will be delayed or not be successful; the risk that BiondVax may not be able to secure additional capital on attractive terms, if at all; the risk that the European Investment Bank may accelerate the loans under its finance contract with BiondVax; the risk that BiondVax may not execute a strategic alternative to M-001 or implement a strategy that will diversify BiondVax's risk, and, if executed, may not be successful; risks relating to the COVID-19 (coronavirus) pandemic; BiondVax's ability to acquire rights to additional product opportunities; BiondVax's ability to enter into collaborations on terms acceptable to BiondVax or at all; timing of receipt of regulatory approval of BiondVax's manufacturing facility in Jerusalem, if at all or when required; the risk that the manufacturing facility will not be able to be used for a wide variety of applications and other vaccine and treatment technologies, and the risk that drug development involves a lengthy and expensive process with uncertain outcomes. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's Annual Report on Form 20-F filed with the Securities and Exchange Commission on May 13, 2021. BiondVax undertakes no obligation to revise or update any forward-looking statement for any reason.
View original content:https://www.prnewswire.com/news-releases/biondvax-to-present-at-hc-wainwright-7th-annual-israel-conference-301423853.html
SOURCE BiondVax Pharmaceuticals Ltd.
FAQ
What is BiondVax Pharmaceuticals presenting at the H.C. Wainwright Conference?
When is the BiondVax presentation scheduled?
What does BiondVax Pharmaceuticals focus on?
How many clinical trials has BiondVax conducted?
Where can investors register to attend the BiondVax presentation?
